<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681170</url>
  </required_header>
  <id_info>
    <org_study_id>APH-19</org_study_id>
    <nct_id>NCT04681170</nct_id>
  </id_info>
  <brief_title>Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)</brief_title>
  <official_title>Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amryt Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amryt Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label, multi centre phase III study to evaluate the efficacy and&#xD;
      long term safety of lomitapide in paediatric patients with HoFH receiving stable LLT&#xD;
      (including LA, when applicable) comprising of the following phases:&#xD;
&#xD;
        -  Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6&#xD;
           weeks)&#xD;
&#xD;
        -  Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6&#xD;
           weeks prior to Baseline for a minimum of 6 weeks):&#xD;
&#xD;
        -  Efficacy Phase (starting at Baseline, i.e. Day [D] 0 for 24 weeks±3 days&#xD;
&#xD;
        -  Safety Phase (starting at Week 24±3 days for 80±1 weeks)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lomitapide has been approved for use in adult patients with HoFH in the European Union (EU)&#xD;
      and European Economic Area (EEA), United States of America (USA), Israel, Argentina, Canada,&#xD;
      Colombia, and Japan. This study is designed to determine if lomitapide is effective and can&#xD;
      be safely administered to paediatric patients with HoFH. If the efficacy and safety so far&#xD;
      observed in adults is confirmed in paediatric patients, the potential exists to significantly&#xD;
      lower LDL C levels in paediatric patients with HoFH. Furthermore, the lower LDL C levels may&#xD;
      reduce atherosclerosis progression and would be expected to benefit these paediatric patients&#xD;
      with HoFH.&#xD;
&#xD;
      A single arm, non comparator design has been selected due to the rarity of the disease and&#xD;
      because the evaluation of safety variables such as growth and sexual maturation requires&#xD;
      longer term observation than would be feasible in the context of a placebo controlled study.&#xD;
&#xD;
      To mitigate the disadvantages of a single arm design, the study includes a Run in Period of&#xD;
      at least 6 weeks during which current LLT (including LA, when applicable) will be stabilised&#xD;
      to establish baseline levels allowing each patient to serve as his/her own control. Patients&#xD;
      will also remain on stable LLT (including LA, when applicable) during the Efficacy Phase of&#xD;
      the study through Week 24±3 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint Percent change in LDL C</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
    <description>To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints AE reporting</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
    <description>Incidence, severity, and relatedness of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline at Week 24±3 days for the following lipid parameters: TC, Non HDL C, VLDL C, TG, Lp(a), and apoB</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline at all other time points through Week 104±1 week for the following lipid parameters: LDL C, TC, Non HDL C, VLDL C, TG, Lp(a), and apo B</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in LLT and LA from Week 24±3 days through Week 104±1 week</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Total number and percent of patients achieving the EAS recommended target LDL C of &lt;135 mg/dL (3.5 mmol/L) in paediatric HoFH patients at Week 24±3 days and at any time on study</measure>
    <time_frame>Baseline through Week 104±1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Homozygous Familial Hypercholesterolaemia (HoFH)</condition>
  <arm_group>
    <arm_group_label>Age 5-10 years</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age11-15years</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 to ≤17 years</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomitapide</intervention_name>
    <description>2mg,5mg, 10mg and 20mg capsules</description>
    <arm_group_label>16 to ≤17 years</arm_group_label>
    <arm_group_label>Age 5-10 years</arm_group_label>
    <arm_group_label>Age11-15years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Male and female patients aged 5 to ≤17 years with HoFH as defined by any of the&#xD;
             following criteria recommended by the Consensus Panel on Familial&#xD;
             Hypercholesterolaemia of the EAS (Cuchel, Bruckert et al. 2014):&#xD;
&#xD;
               1. Genetic confirmation of 2 mutant alleles at the LDL receptor (LDLR), apo B,&#xD;
                  Proprotein convertase subtilisin/kexin type 9 (PCSK9), or LDL receptor adapter&#xD;
                  protein 1 (LDLRAP1) gene locus OR&#xD;
&#xD;
               2. An untreated LDL C &gt;500 mg/dL (13 mmol/L) or treated LDL C ≥300 mg/dL (8 mmol/L )&#xD;
                  together with either Cutaneous or tendon xanthoma before age 10 years or&#xD;
                  Untreated LDL C levels consistent with heterozygous FH in both parents&#xD;
&#xD;
          -  Baseline LDL C on LLT (maximum concentration [Cmax] immediately prior to LA, if&#xD;
             applicable)&#xD;
&#xD;
               1. &gt;160 mg/dL (4.1 mmol/L, no documented cardiovascular disease [CVD]) or&#xD;
&#xD;
               2. &gt;130 mg/dL (3.4 mmol/L, established CVD defined as aortic valve disease and/or&#xD;
                  coronary atherosclerosis)&#xD;
&#xD;
          -  Body weight ≥15 kg or BMI and height both &gt;10th percentile according to World Health&#xD;
             Organization (WHO) Growth Charts for Boys and Girls 5 to 19 Years of Age&#xD;
&#xD;
          -  Patient and/or his/her legal representative has/have been informed, has/have read and&#xD;
             understood the patient information/informed consent form, and has/have given written&#xD;
             informed assent/consent&#xD;
&#xD;
          -  Patient and/or his/her legal representative must be able and willing to follow study&#xD;
             procedures and instructions, particularly that&#xD;
&#xD;
               1. LLT (including LA, when applicable) must be stable for at least 6 weeks prior to&#xD;
                  Baseline (Run in Period) and remain stable through Week 24±3 days (end of&#xD;
                  Efficacy Phase)&#xD;
&#xD;
               2. The patient must be compliant with both the low fat diet supplying &lt;20% of energy&#xD;
                  (calories) from fat or &lt;30 g fat, whichever is the lesser amount starting at the&#xD;
                  beginning of the Run in Period and the dietary supplement regimen starting at&#xD;
                  Week 2 of the Run in Period, both continuing until completion of the study&#xD;
&#xD;
          -  Postmenarchal female adolescents must be willing to use an effective form of birth&#xD;
             control with failure rates &lt;1% per year (e.g., implant, injectable, combined oral&#xD;
             contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomy or&#xD;
             vasectomised partner) during participation in the study (and at least 4 weeks&#xD;
             thereafter). Patients taking oestrogen based oral contraceptives should be advised&#xD;
             about possible loss of effectiveness due to diarrhea and/or vomiting. Additional&#xD;
             contraceptive measures should be used for 7 days after resolution of symptoms.&#xD;
&#xD;
          -  Patient must be in stable physical and mental health at screening&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Other forms of primary hyperlipoproteinaemia and secondary causes of&#xD;
             hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism)&#xD;
&#xD;
          -  Contraindications for the use of lomitapide according to section 4.3 of the European&#xD;
             Medicines Agency (EMA) Summary of Product Characteristics (SmPC), such as&#xD;
             hypersensitivity to the active substance or to any of the excipients listed in Section&#xD;
             6.1 of the SmPC, known significant or chronic inflammatory bowel disease or&#xD;
             malabsorption&#xD;
&#xD;
          -  Moderate (Child Pugh B) or severe hepatic impairment (Child Pugh C), active liver&#xD;
             disease and/or abnormal liver function tests at screening (AST or ALT &gt;1.5 x upper&#xD;
             limit of normal (ULN) and/or total bilirubin &gt;1.5 x ULN in the absence of Gilbert's&#xD;
             syndrome or AP &gt;1.5 x ULN [based on appropriate age and gender normal values])&#xD;
&#xD;
          -  Serum CK &gt;2 x ULN&#xD;
&#xD;
          -  Chronic renal insufficiency with glomerular filtration rate (GFR) &lt;70 mL/min/1.73 m2&#xD;
             calculated using the Schwartz formula&#xD;
&#xD;
          -  Uncontrolled hypertension (defined as mean systolic and/or diastolic blood pressure&#xD;
             ≥95% of normal for age and sex) despite medical therapy&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV congestive heart failure&#xD;
&#xD;
          -  Precocious/delayed puberty or endocrine disorder affecting growth (e.g.,&#xD;
             hypothyroidism, premature adrenarche)&#xD;
&#xD;
          -  History of drug abuse within the last 3 years or habitual alcohol consumption (defined&#xD;
             as &gt;1 ounce [28 g] of liquor or 4 ounce glass [113 g] of wine, or the equivalent, ≥3&#xD;
             times per week)&#xD;
&#xD;
          -  Life expectancy predicted to be &lt;5 years&#xD;
&#xD;
          -  History of a non skin malignancy (with the exception of cervical cancer in situ)&#xD;
             within 3 years prior to enrolment&#xD;
&#xD;
          -  Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times&#xD;
             the terminal half life of the corresponding IMP, whichever is longer, before the&#xD;
             screening visit&#xD;
&#xD;
          -  Patient is a dependent of the sponsor, of the investigational team or his/her&#xD;
             immediate family&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruth Nallen</last_name>
    <phone>+35315180200</phone>
    <email>aph19@amrytpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Monitor</last_name>
    <phone>+35315180200</phone>
    <email>APH19medicalmonitor@amrytpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universtiats-Kinderlinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus P Schmitt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claus P Schmitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Taylan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christina Taylan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun OH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jun OH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof R Shaoul</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan,</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O.C. Clinica Medica 1</name>
      <address>
        <city>Padova</city>
        <state>Padua</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Zambon, Prof</last_name>
    </contact>
    <investigator>
      <last_name>A Zambon, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.R.N. &quot;Sant' Anna e San Sebastiano&quot; di Caserta</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Calabreò, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Children's Hospital,</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr S Buonuomo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdullah International Medical Research Centre (KAIMRC),</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr M Al-Dubayee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr A Alashwal</last_name>
    </contact>
    <investigator>
      <last_name>Prof A Alashwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan</name>
      <address>
        <city>Reus</city>
        <state>Tarragona,</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Luis Masana Martin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Abente y Lago</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Jose L Diaz-Diaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario of Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sergio Martinez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>E.P.S. Fattouma Bourguiba Hospital</name>
      <address>
        <city>Monastir,</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr F Maatouk</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

